Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 3

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Blood Protein Disorders 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × ricolinostat × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

NCT02091063 2024-08-06

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

Columbia University

Phase 1/2 Terminated
23 enrolled 6 charts
LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT01323751 2017-04-06

ACY-1215

Celgene

Phase 1/2 Completed
120 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡